-
2026-08-13
GenSci's Ophthalmology Pipeline: IND Approval Secured for Three IndicationsLearn More
-
2026-07-31
GenSci144, a Novel SLC6A19 Inhibitor, Receives IND Approval from NMPALearn More
-
2026-07-30
Gensci's VEGFR2 mAb NDA Accepted by NMPALearn More
-
2026-07-30
GenSci098 Receives FDA Fast Track Designation and Advances into Phase 2 Clinical TrialsLearn More
-
2026-06-24
GenSci's Triptorelin Acetate for Injection (II) Secures NMPA Approval for Central Precocious PubertyLearn More
-
2026-06-04
GenSci: Two Innovations Granted IND Clearance by FDALearn More
-
2026-05-28
Dr. Lei Jin of GenSci Shines at J.P. Morgan Global China Summit, Sharing Insights on Innovation and GlobalizationLearn More
-
2026-05-19
GenSci's Innovative IL-1α/β Bispecific Antibody Receives First FDA Clinical ApprovalLearn More
-
2026-05-15
GenSciP166 Selected as Late-Breaking Abstract at SID 2026Learn More
-
2026-05-07
GenSci's Firsekibart Injection Receives Approval by NMPALearn More